Gupta Priti, Singh Kalpana, Shivashankar Roopa, Singh Kavita, Vamadevan Ajay, Mohan V, Kadir Muhammad Masood, Tandon Nikhil, Narayan K M, Prabhakaran Dorairaj, Ali Mohammed K
Centre for Chronic Disease Control, New Delhi, India
Centre for Chronic Disease Control, New Delhi, India.
BMJ Open. 2020 Sep 30;10(9):e036317. doi: 10.1136/bmjopen-2019-036317.
To estimate average annual expenditures per person, total economic burden and distress health financing associated with the treatment of five cardio-metabolic diseases (CMDs-hypertension, diabetes, heart disease (angina, myocardial infarction and heart failure), stroke and chronic kidney disease) in three metropolitan cities in South Asia.
Cross-sectional surveys.
We analysed community-based baseline data from the Centre for cArdio-metabolic Risk Reduction in South Asia (CARRS) Study collected in 2010-2011 representing Chennai and New Delhi (India), and Karachi (Pakistan).
We used data from non-pregnant adults (≥20 years) from the aforementioned cities that responded to a cost-of-illness questionnaire. We estimated health utilisation and expenditures among those reporting taking treatment(s) for the aforementioned CMDs in the last 1 year. We converted all costs to International Dollars (Int$ 2011) and inflated to 2018 values. The annual costs per person were stratified by city, sociodemographic characteristics, contributor of costs and financing methods. The total economic burden of CMDs for each city was projected using age-standardised prevalence and per-person costs of diseases reported in CARRS, applying these to population data from the most recent census. We also calculated distress financing (DF) as having to borrow or sell assets to pay for CMD treatment and identified sociodemographic groups at most risk of DF using multiple regression.
Of 16 287 CARRS participants, 2883 (17.7%) reported receiving treatment for CMDs. The total annual expenditures reported per patient for CMDs ranged from Int$358 to Int$2425. Medications constituted 46% of total direct expenditures and out-of-pocket (OOP) expenditures accounted for nearly 80% of financing these health expenditures. Total economic burdens of CMDs were Int$0.42 billion, Int$3.4 billion and Int$1.4 billion in Chennai, New Delhi and Karachi, respectively. Overall, 36.1% experienced DF, and women (OR=4.4), unemployed (OR=10.7) and uninsured (OR=8.1) adults experienced higher odds of DF.
CMDs are associated with large economic burdens in South Asia. Due to most payments coming from OOP expenditures and limited insurance, the odds of DF are high.
估算南亚三个大城市中与治疗五种心血管代谢疾病(CMDs,即高血压、糖尿病、心脏病(心绞痛、心肌梗死和心力衰竭)、中风和慢性肾病)相关的人均年支出、总经济负担和窘迫性卫生筹资情况。
横断面调查。
我们分析了南亚心血管代谢风险降低中心(CARRS)研究于2010 - 2011年收集的基于社区的基线数据,该数据代表印度的钦奈和新德里以及巴基斯坦的卡拉奇。
我们使用了上述城市中对疾病成本问卷做出回应的非孕成年人(≥20岁)的数据。我们估算了在过去1年中报告接受上述CMDs治疗的人群的医疗利用情况和支出。我们将所有成本换算为国际美元(2011年国际美元)并通胀至2018年的值。人均年成本按城市、社会人口学特征、成本贡献者和筹资方式进行分层。每个城市CMDs的总经济负担是根据CARRS报告的疾病年龄标准化患病率和人均成本,应用于最新人口普查的人口数据来预测的。我们还将窘迫性筹资(DF)计算为不得不借款或出售资产来支付CMDs治疗费用,并使用多元回归确定DF风险最高的社会人口学群体。
在16287名CARRS参与者中,2883人(17.7%)报告接受了CMDs治疗。每位患者报告的CMDs年度总支出从358国际美元到2425国际美元不等。药物占总直接支出的46%,自付(OOP)支出占这些卫生支出筹资的近80%。钦奈、新德里和卡拉奇的CMDs总经济负担分别为4.2亿美元、34亿美元和14亿美元。总体而言,36.1%的人经历了DF,女性(比值比=4.4)、失业者(比值比=10.7)和未参保成年人(比值比=8.1)经历DF 的几率更高。
CMDs在南亚造成了巨大的经济负担。由于大多数支付来自OOP支出且保险有限,DF的几率很高。